Were the Cadrenal Therapeutics (CVKD) CEO’s share sales pre-planned under a Rule 10b5-1 plan?

Yes. The filing states the CEO’s sales were executed under a Rule 10b5-1 trading arrangement. This plan was adopted on September 25, 2025, meaning the trades were pre-arranged rather than timed discretionarily after that adoption date.

What were the prices for the Cadrenal Therapeutics (CVKD) CEO’s recent share sales?

The reported weighted average sale prices were $5.76, $5.28, and $4.93 per share. Footnotes explain that each price reflects multiple trades within ranges of $5.47–$6.12, $5.07–$5.535, and $4.81–$5.07, respectively, during each trading day.

Cadrenal (CVKD) CEO sells 12,763 shares, retains direct and trust holdings

Filing Impact

(Neutral)

Filing Sentiment

(Negative)

Form Type

Rhea-AI Filing Summary

Cadrenal Therapeutics, Inc. CEO and Chairman Quang X Pham reported open-market sales of 12,763 shares of common stock. The sales occurred on May 11, May 12, and May 28, 2026, at reported weighted average prices of $5.76, $5.28, and $4.93 per share.

The footnotes state these transactions were made under a Rule 10b5-1 trading arrangement adopted on September 25, 2025. Following the latest sale, Pham holds 182,161 shares directly and 200,000 shares indirectly through The PVBQ Living Trust, where he has sole voting and dispositive power. The filing also corrects an earlier understatement of indirect holdings on a prior Form 4.

Insider Trade Summary 10b5-1

Net Seller: 12,763 shares ($69,451)

Net Sell 4 txns

Insider Pham Quang X

Role CEO and Chairman

Sold 12,763 shs ($69K)

Type	Security	Shares	Price	Value
Sale	Common Stock	2,989	$4.93	$15K
Sale	Common Stock	3,298	$5.28	$17K
Sale	Common Stock	6,476	$5.76	$37K
holding	Common Stock	--	--	--

Holdings After Transaction: Common Stock — 182,161 shares (Direct, null); Common Stock — 200,000 shares (Indirect, The PVBQ Living Trust)

Footnotes (1)

Represents shares of the Issuer's common stock sold by the Reporting Person in accordance with a Rule 10b5-1 trading arrangement adopted by the Reporting Person on September 25, 2025. The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $5.47 through $6.12. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer or the Staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. The total shares reported as directly owned in Column 5 takes into account subsequent transactions effected by the Reporting Person and reported on a Form 4 filed on May 26, 2026. The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $5.07 through $5.535. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer or the Staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $4.81 through $5.07. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer or the Staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. On May 26, 2026, the Reporting Person filed a Form 4 which inadvertently understated in Column 5 the number of shares indirectly owned by the Reporting Person. This inadvertent understatement has been corrected in this filing. Quang Pham is the Trustee of The PVBQ Living Trust and has sole voting and dispositive power with respect to the shares owned by The PVBQ Trust, of which Mr. Pham's child is the sole beneficiary.

Key Figures

Total shares sold: 12,763 shares Sale price May 11, 2026: $5.76 per share Sale price May 12, 2026: $5.28 per share +4 more

7 metrics

Total shares sold 12,763 shares Open-market sales on May 11, 12 and 28, 2026

Sale price May 11, 2026 $5.76 per share Weighted average price for 6,476 shares sold

Sale price May 12, 2026 $5.28 per share Weighted average price for 3,298 shares sold

Sale price May 28, 2026 $4.93 per share Weighted average price for 2,989 shares sold

Direct holdings after latest sale 182,161 shares Common stock directly owned after May 28, 2026 transaction

Indirect trust holdings 200,000 shares Common stock held via The PVBQ Living Trust

Trading plan adoption date September 25, 2025 Rule 10b5-1 trading arrangement adoption

Key Terms

Rule 10b5-1 trading arrangement, weighted average price, The PVBQ Living Trust, indirectly owned, +1 more

5 terms

Rule 10b5-1 trading arrangement regulatory

"shares of the Issuer's common stock sold ... in accordance with a Rule 10b5-1 trading arrangement"

weighted average price financial

"The price reported in Column 4 is a weighted average price."

Weighted average price is the average price of a security where each trade or component is counted according to its size, so bigger trades pull the average more than smaller ones. Think of it like calculating the average cost of a grocery haul where items you bought more of have greater influence on the final per-item cost. Investors use it to understand the true average price paid or received, judge execution quality, and compare trading performance against market movement.

The PVBQ Living Trust financial

"Quang Pham is the Trustee of The PVBQ Living Trust and has sole voting and dispositive power"

indirectly owned financial

"understated in Column 5 the number of shares indirectly owned by the Reporting Person"

Form 4 regulatory

"On May 26, 2026, the Reporting Person filed a Form 4 which inadvertently understated"

Form 4 is a official document that company insiders, such as executives or major shareholders, file with regulators whenever they buy or sell company shares. It provides transparency about how those with inside knowledge are trading, helping investors see if insiders are confident in the company's prospects or may be selling for personal reasons. This information can influence investor decisions by revealing insiders' perspectives on the company's value.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google

Form 4 Insider Transactions: What Each Field Means →

05/29/2026 - 04:30 PM

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Pham Quang X

(Last)

(First)

(Middle)

C/O CADRENAL THERAPEUTICS, INC.

822 A1A NORTH, SUITE 306

(Street)

PONTE VEDRA

FLORIDA

32082

(City)

(State)

(Zip)

UNITED STATES

(Country)

2. Issuer Name and Ticker or Trading Symbol
Cadrenal Therapeutics, Inc. [ CVKD ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director	X	10% Owner
X	Officer (give title below)		Other (specify below)
	CEO and Chairman

2a. Foreign Trading Symbol

3. Date of Earliest Transaction (Month/Day/Year)
05/11/2026

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	Code	V	Amount	(A) or (D)	Price		6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
Common Stock	05/11/2026		S		6,476⁽¹⁾	D	$5.76⁽²⁾	188,448⁽³⁾	D
Common Stock	05/12/2026		S		3,298⁽¹⁾	D	$5.28⁽⁴⁾	185,150⁽³⁾	D
Common Stock	05/28/2026		S		2,989⁽¹⁾	D	$4.93⁽⁵⁾	182,161	D
Common Stock								200,000⁽⁶⁾	I	The PVBQ Living Trust⁽⁷⁾

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares	8. Price of Derivative Security (Instr. 5)		10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)

Explanation of Responses:

1. Represents shares of the Issuer's common stock sold by the Reporting Person in accordance with a Rule 10b5-1 trading arrangement adopted by the Reporting Person on September 25, 2025.

2. The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $5.47 through $6.12. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer or the Staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.

3. The total shares reported as directly owned in Column 5 takes into account subsequent transactions effected by the Reporting Person and reported on a Form 4 filed on May 26, 2026.

4. The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $5.07 through $5.535. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer or the Staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.

5. The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $4.81 through $5.07. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer or the Staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.

6. On May 26, 2026, the Reporting Person filed a Form 4 which inadvertently understated in Column 5 the number of shares indirectly owned by the Reporting Person. This inadvertent understatement has been corrected in this filing.

7. Quang Pham is the Trustee of The PVBQ Living Trust and has sole voting and dispositive power with respect to the shares owned by The PVBQ Trust, of which Mr. Pham's child is the sole beneficiary.

	/s/ Quang X. Pham	05/29/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)

Source: View Original Filing on SEC EDGAR

FAQ

What insider stock transactions did Cadrenal Therapeutics (CVKD) report for its CEO?

Cadrenal’s CEO reported selling 12,763 common shares in three open-market transactions. These sales occurred on May 11, May 12, and May 28, 2026, at weighted average prices of $5.76, $5.28, and $4.93 per share, respectively.

How many Cadrenal Therapeutics (CVKD) shares does the CEO hold after these transactions?

After the reported sales, the CEO holds 182,161 shares directly and 200,000 shares indirectly. The indirect shares are owned through The PVBQ Living Trust, where he has sole voting and dispositive power, giving him control over those trust-held shares.

Did the Cadrenal Therapeutics (CVKD) Form 4 correct any prior reporting errors?

Yes. The filing notes a prior Form 4 understated indirectly owned shares. A footnote explains that an earlier Form 4 filed on May 26, 2026 understated the number of shares indirectly owned, and that understatement is corrected in this filing’s reported indirect holdings.

How are the Cadrenal Therapeutics (CVKD) CEO’s indirect holdings structured?

The CEO’s indirect holdings are held through The PVBQ Living Trust. He serves as trustee and has sole voting and dispositive power over 200,000 shares owned by the trust, whose sole beneficiary is his child, according to the footnote disclosure.